Actively Recruiting

Age: 18Years - 99Years
All Genders
Healthy Volunteers
NCT02995252

The HOPE Study: Characterizing Patients With Hepatitis B and C

Led by University of Maryland, Baltimore · Updated on 2025-05-15

550

Participants Needed

2

Research Sites

1043 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C. Participants will be seen on an annual basis with optional additional visits for up to 10 years and provide samples for research and evaluation of disease progression. In addition, there is a longitudinal sub-study for treatment of hepatitis B that will involve 2 years of treatment with tenofovir alafenamide and blood collections with optional liver biopsies.

CONDITIONS

Official Title

The HOPE Study: Characterizing Patients With Hepatitis B and C

Who Can Participate

Age: 18Years - 99Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • At least 18 years old
  • Infected with hepatitis B and/or C, or have a history of hepatitis B infection but cleared, or have been successfully treated for hepatitis C with direct acting antiviral agents, with or without HIV infection, or be a healthy volunteer without a history of hepatitis B, hepatitis C, or HIV
  • Willing to have samples stored for future research
  • Must have an identifiable primary care provider or be in the process of establishing one
  • Willing to undergo HIV testing if not recently documented
  • Eligibility for the hepatitis B treatment sub-study depends on meeting criteria for nucleos(t)ide analogue therapy according to standard care
Not Eligible

You will not qualify if you...

  • Unable to comply with research study visits
  • Poor venous access preventing laboratory collection
  • Any condition the investigator considers a contraindication to study participation
  • For hepatitis B monoinfected participants, any contraindications to nucleos(t)ide analogue treatment excludes participation in the hepatitis B treatment sub-study
  • Pregnant or breastfeeding women are not eligible for the hepatitis B treatment sub-study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Institute of Human Virology, University of Maryland School of Medicine

Baltimore, Maryland, United States, 21201

Actively Recruiting

2

Dr Huong Dang, Medical Practice

Falls Church, Virginia, United States, 22044

Actively Recruiting

Loading map...

Research Team

L

Lydia Tang, MBChB

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here